| Literature DB >> 34867067 |
Abstract
COVID-19 (Coronavirus Disease 2019) pandemic highlighted the importance of air biosecurity because SARS-CoV-2 is mainly transmitted from person to person via airborne droplets. Preventing infectious droplets from entering the body is one of the best ways to protect against infection. This paper reviews the transmission patterns of airborne pathogens and air disinfection methods. A particular emphasis is put on studies devoted to the thermal inactivation of viruses. These reviews reveal that air heat treatment has not been seriously considered as a possible air disinfection approach. Simple calculations show that the energy input required for thermal disinfection of human's air daily consumption is almost the same as for daily water consumption (by heat treatment from room temperature to 100 °C). Moreover, it is possible to organize a continuous heat recovery from the air already heated during disinfection to the inlet air, thus significantly increasing the energy efficiency. Therefore, I propose a solution for the thermal inactivation of airborne pathogens based on air heating and its subsequent cooling in a heat exchanger with heat recovery. Such a solution could be used to create mobile personal and stationary indoor air disinfectors, as well as heating, ventilation, and air conditioning systems. Thermal disinfection of air to breathe might one day be part of people's daily life like thermal disinfection of drinking water. Aside from limiting infectious disease transmission, thermal inactivation might be the basis for developing inhaled vaccines using thermally inactivated whole pathogens.Entities:
Year: 2021 PMID: 34867067 PMCID: PMC8628600 DOI: 10.1016/j.applthermaleng.2021.117855
Source DB: PubMed Journal: Appl Therm Eng ISSN: 1359-4311 Impact factor: 5.295
Infective dose of some viruses.
| Virus | Host | Administration method | Dose | Effect | Source |
|---|---|---|---|---|---|
| Avian influenza virus A/Chicken/Shandong/01/2008 (H9N2) | Chicken | Aerosol | 42 151.59, | Number infected: 10 of 10, 9 of 10, 4 of 10, 1 of 10, and 0 of 10, respectively (median dose 491 TCID50) | |
| Influenza virus strain A2/Bethesda/10/63 | Men aged from 21 to 41 | Aerosol | For volunteers without neutralizing antibodies – 1 to 5 TCID50 | 3 illness among 9 volunteers | |
| Influenza virus strain A/Kawasaki/9/86 (H1N1) | Volunteers aged from 18 to 50 | Intranasal | 107 TCID50 | 26 of 54 people became ill | |
| Rhinovirus NIH 1734 | Men | Aerosol | 16, 20 and 66 TCID50 | all 8 volunteers became ill | |
| Adenovirus type 4 | Men | Aerosol | 171, 5–11, 1–2 and 0.1 TCID50 | Number ill: 4 out of 4, 8 out of 9, 3 out of 5, 0 out of 3 volunteers, respectively | |
| SARS-CoV-1 | Model (for apartment residents) | Aerosol | from 16 to 160 PFU | The ratio of the number of cases to the total number of residents ranged from 0.038 to 0.325, respectively | |
| MERS-CoV mouse-adapted strain (icMERSma1) | Mouse | Intranasal | from 103 to 105 PFU | Such doses may cause severe respiratory disease | |
| MERS-CoV strain EMC/2012 | hCD26/DPP4 transgenic mice | Intranasal | from 1.25 to 10 TCID50 and from 102 to 106 | doses of 1.25 to 10 TCID50 caused infection in 75–100 % of challenged mice, doses of 102 to 106 caused death in 100 % of challenged mice | |
| SARS-CoV-2 | hACE2 transgenic mice | Close contact, via respiratory droplets and aerosol | 36 TCID50/min for aerosol method | Close contact infected 7 out of 13 animals, 3 out of 10 animals were infected through respiratory droplets, aerosol contamination needs time greater than 25 min | |
| SARS-CoV-2 | Ferrets | Intranasal | 5·106, 5·104 and 5·102 PFU | viral RNA isolation in the upper respiratory tract in 6 out of 6 animals for high and medium doses, and 1 out of 6 for low dose |
The concentration of viruses in the air near infected animals.
| Virus | Content in 1 m3 of air | Source |
|---|---|---|
| Swine fever virus | 104 TCID50 | |
| Aujeszky's disease virus in pig | 105,3 TCID50 | |
| Foot-and-mouth disease in pig | 103 TCID50 | |
| Newcastle disease virus in chicken | 104 PFU |
The concentration of human viruses in the air under various conditions.
| Virus | Conditions | Content in 1 m3 of air, viral genome copies | Source |
|---|---|---|---|
| Influenza | in a health center at the Virginia Institute of Technology (USA) during the 2009–2010 flu season | 5.8·103-1.6·104 | |
| in a day-care facility in Blacksburg, Virginia (USA), during the 2009–2010 flu season | 1.6·104-3.7·104 | ||
| on board at Roanoke Airport, Virginia (USA) during the 2009–2010 flu season | 1.1–1.4·104 | ||
| SARS-CoV-2 | outdoors in northern and southern Italy during the 2020 pandemic | <0.8 | |
| SARS-CoV-2 | outdoors in northern Italy during the 2020 pandemic | <1 | |
| SARS-CoV-2 | in hospital rooms with infected patients | 1-2·103 | |
| SARS-CoV-2 | in the rooms and corridor of the hospital | 2·103 | |
| near an infected patient | 4·103 |
The inactivation rate of viruses in aerosols. T - temperature, RH - relative humidity.
| Virus | Conditions | Half-life | Source |
|---|---|---|---|
| Swine fever virus | T = 21–22 °C, RH = 60–74 % | from 4.5 to 15 min | |
| Vaccinia virus | T = 10.5–11.5 °C, RH = 20 % | more than 23 h | |
| T = 21–23 °C, RH = 48–51 % | about 6 h | ||
| T = 31.5–33.5 °C, RH = 50 % | about 1 h | ||
| T = 31.5–33.5 °C, RH = 80–83 % | about 0.5 h | ||
| Influenza virus type A, strain PR 8 | T = 7–8 °C, RH = 23–25 % | more than 23 h | |
| T = 20.5–24 °C, RH = 50–51 % | about 0.5 h | ||
| T = 20.5–24 °C, RH = 81 % | about 5 min | ||
| T = 32 °C, RH = 20 % | from 0.5 to 1 h | ||
| T = 32 °C, RH = 81 % | about 5 min | ||
| Poliovirus type I | T = 20 ± 1 °C, RH = 80 ± 5 % | 9.07 ± 1.82 h | |
| Human coronavirus 229E | T = 6 ± 1 °C, RH = 30 ± 5 % | 34.46 ± 3.21 h | |
| T = 6 ± 1 °C, RH = 50 ± 5 % | 102.53 ± 9.38 h | ||
| T = 6 ± 1 °C, RH = 80 ± 5 % | 86.01 ± 5.28 h | ||
| T = 20 ± 1 °C, RH = 30 ± 5 % | 26.76 ± 6.21 h | ||
| T = 20 ± 1 °C, RH = 50 ± 5 % | 67.33 ± 8.24 h | ||
| T = 20 ± 1 °C, RH = 80 ± 5 % | 3.34 ± 0.16 h | ||
| SARS-CoV-1 | T = 21–23 °C, RH = 65 % | about 1.2 h | |
| SARS-CoV-2 | T = 21–23 °C, RH = 65 % | about 1.1 h |
Methods used today to eliminate airborne pathogens: advantages and disadvantages
| Method | Advantages | Disadvantages and limitations | |
|---|---|---|---|
| Ultraviolet germicidal irradiation (UVGI) | Mercury-based lamps | - mature technology; | - the short lifespan and frequent replacement; |
| LED-based lamps | - suitable for various applications; | - limited LED output power; | |
| Alternative ultraviolet-based solutions (xenon pulsed light, chip technology) | - suitable for various applications; | - uncertain lamp life; | |
| Filtration | - easily accessible (face masks); | - low efficacy of conventional medical masks; | |
| Ventilation | - high reliability; | - large investments; | |
| Photocatalytic oxidation | - non-toxicity; | - decreasing efficiency due to deposits of inactivated residues on the catalyst; | |
| Plasma inactivation | - shortened size and mass of a device; | - negative impact of reactive oxygen or nitrogen radicals on air quality and human health. | |
| Nanomaterials | - broad-spectrum antiviral properties | - decrease in air quality; | |
| Essential oils | - easily accessible; | - negative impact of essential oil components on the human organism during prolonged use. | |
Inactivation of viruses at high temperatures.
| Virus | Temperature, time | Medium/conditions | Inactivation efficiency | Source |
|---|---|---|---|---|
| Human influenza virus A/Wisconsin/67/2005 (H3N2) | 35.0, 38.3, 43.7, 49.6, 55.6, 61.3, 66.7 and 70 °C during 30 min | Cell culture supernatants (concentration 104.8 TCID50/ml) | The virus is completely inactivated at temperatures ≥ 55.6 °C | |
| Avian influenza virus A/Mallard/NL/12/00 (H7N3) | 35.0, 38.3, 43.7, 49.6, 55.6, 61.3, 66.7 and 70 °C during 30 min | Cell culture supernatants (concentration 105.3 TCID50/ ml) | The virus is completely inactivated at temperatures ≥ 55.6 °C | |
| Avian influenza viruses A/Anhui/1/2013 and A/Shanghai/1/2013 (H7N9) | 56, 65, 70, 75, 100 °C during 1–60 min | The solution containing 107.7 50% of the infectious dose of eggs per ml | Viruses are completely inactivated at 56 °C for 30 min, at 65 °C for 10 min, at 70 °C, 75 °C, and 100 °C for 1 min | |
| Avian influenza virus H5N1 | 4, 28 and 56 °C | Suspension | The virus remained active at 4 °C after 100 days, inactivated at 28 °C after 24 h, and at 56 °C after 30 min | |
| Foot and mouth disease virus | from 72 to 95 °C, treatment time 18.6 or 36 s | Milk of infected cow (virus concentration 104 PFU) | Reduction of titer by 4 logs (below the detection limit) | |
| SARS-CoV-2 | 4, 22 and 70 °C | Culture with virus content 6–8 log TCID50/ ml (detection limit 100 TCID50/ml) | The virus titer decreased 0.7 logs at 4 °C after 14 days. At 70 °C, the virus was inactivated after 5 min. | |
| SARS-CoV-2 | Protocols: 56 °C and 30 min, 60 °C and 60 min, 92 °C and 15 min | Cell culture supernatants, blood serum, and saliva samples from the nasopharynx of an infected person (initial concentration 105 to 106 TCID50/ml, detection limit 100.5 TCID50/ml) | In all cases, a 5 log drop in TCID50 was observed. The activity was retained only in cell culture supernatants at 56 °C/30 min and 60 °C/60 min. | |
| SARS-CoV-2 | 56 °C, 65 °C, and 95 °C, time to 60 min | Cell culture supernatants, nasopharyngeal and serum samples (concentration 106 TCID50/ml, detection limit 100.67 TCID50/ml) | The virus is inactivated after 30 min, 15 min, and 3 min at 56 °C, 65 °C, and 95 °C, respectively. | |
| SARS-CoV-2 | 70 °C, time to 90 min | Cell culture (concentration 105 TCID50/ml, detection limit 100.5 TCID50/ml) | Virus half-life 0.86 min when using closed tubes and 37 min in open dishes in a dry oven | |
| MERS-CoV | 25, 56 and 65 °C, time to 120 min | Cell culture (concentration 105.59 TCID50/ml, detection limit 100.67 TCID50/ml) | Inactivation at 56 °C for 60 min, at 65 °C for 15 min. It takes 25 and 1 min to decrease TCID50 by 4 orders of magnitude at 56 and 65 °C, respectively. At 25 °C, no decrease in titer is observed after 2 h. | |
| Virus MS2 ATCC 15597-B1 | Bubble temperature 150 °C, the temperature of the solution in the vessel 47 °C | A vessel with water and aqueous solutions of salts, through which preheated air bubbles were passed. The volume of the liquid (solution) is 250 ml. The total content of the MS2 virus 7.25·105 | Drop in virus concentration by 2 log | |
| Mouse hepatitis virus MHV-A59 | from 55 ℃ to 170 ℃ | Cell culture (concentration 5·107 PFU/ml). The virus solution is passed through a stainless-steel capillary sequentially through the hot zone and the cold zone. Heating occurs in that part of the capillary that is immersed in heated oil, cooling occurs in that part of the capillary that is immersed in a solution with ice. | At a temperature of 85.2 °C for 0.48 s, the PFU decreases by 5 logs, at a temperature of 83.4 °C for 0.95 s, the virus is completely inactivated | |
| SARS-CoV, SARS-CoV-2, MERS-CoV and others | Up to 100 °C | Modeling | At a temperature of 70 °C, a decrease in concentration by 3 logarithms averaged for all viruses is achieved in 3 min. At temperatures above 80 °C, the estimated time for which the concentration of SARS-CoV-1 and SARS-CoV-2 decreases by 3 orders of magnitude is less than 1 min. | |
| Virus MS2 | Up to 250 °C, time 0.1–1 s | Flow chamber with an axial heater. Two air flows – 18 and 36 l/min. The diameter and length of the chamber are 50 mm and 320 mm, respectively, the diameter and length of the heater are 10 mm and 230 mm, respectively. | A drop in the concentration of the virus in the air by 1 log at 90 °C (18 l/min) and 140 °C (36 l/min). A drop in the concentration of the virus in the air by 3 logs at 150 °C (18 l/min) and 230 °C (36 l/min). | |
| SARS-CoV-2 | Up to 200 °C | Air with viruses was passed through six curved strips of foamed nickel, the size of each strip is 24 cm × 4 cm, and the depth (length of the hot zone) is 1.6 cm. The air flow rate – 10 l/min. | The inactivation efficiency by one pass is 99.8 %. |
Fig. 1Scheme of a proposed solution for thermal inactivation of airborne pathogens. 1 – filter, either coarse or fine; 2 - air supply device; 3 - heat exchanger for heat recovery (to warm the inlet air and cool the outlet air); 4 - heater to warm the air up to the specified maximum temperature; 5 - thermal insulation.
Fig. 2Conceptual sketches of three possible applications of the proposed solution for thermal inactivation of pathogens: a) mobile personal air disinfector, b) stationary indoor air disinfector, and c) within the heating, ventilation, and air conditioning (HVAC) system.